Kaur, Manraj N. http://orcid.org/0000-0002-1911-0395
Cornacchi, Sylvie D.
Tsangaris, Elena
Poulsen, Lotte
Beelen, Louise M.
Bordeleau, Louise
Zhong, Toni
Jorgensen, Mads Gustaf
Sorensen, Jens Ahm
Mehrara, Babak
Dayan, Joseph
Pusic, Andrea L.
Klassen, Anne F.
Funding for this research was provided by:
Canadian Breast Cancer Foundation (319371)
Canadian Cancer Society (706256)
CIHR Canadian Institute for Health Research
Article History
Received: 21 November 2023
Accepted: 15 February 2024
First Online: 26 June 2024
Declarations
:
: Research ethics board approval was obtained from the following institutions: Hamilton Integrated Research Ethics Board for the Juravinski Cancer Center (Hamilton, ON, Canada), and the ethics boards of Toronto General Hospital (Toronto, ON, Canada), Memorial Sloan Kettering Cancer Center (New York, NY, U.S.) and Brigham and Women’s Hospital (Boston, MA, U.S.). In Denmark, the study was reported to and approved by the Region of Southern Denmark and was included on the list of Health Research for data protection safety. <i>Written and verbal consent was obtained from all participants before the interviews and focus groups.</i>
: Not applicable.
: The LYMPH-Q Upper Extremity Module is owned by Memorial Sloan-Kettering Cancer Center, McMaster University, Mass General Brigham, and Pusic and Klassen are co-developers. Anne Klassen owns EVENTUM Research, which provides consulting services to the pharmaceutical industry. The other authors have no competing interests to report concerning the content of this article.